Projects

1 - 4 of 4 results

Search term:

The investigation of arterial stiffness as a potential marker in cardio-oncology. University of Antwerp

Pieter-Jan Guns
Physiopharmacology (PHYSPHAR)
Anthracyclines (such as doxorubicin, DOX) are among the most effective chemotherapeutics and are widely used in modern cancer treatment despite the advent of targeted therapies. However, dosedependent cardiotoxicity limits the clinical use of DOX. It is well documented that DOX may provoke cardiotoxicity leading to left ventricular dysfunction and eventually congestive heart failure. Recent studies have reported that anthracyclines also ...

Is arterial stiffness an overlooked marker in cardio-oncology? University of Antwerp

Pieter-Jan Guns
Cardiovascular diseases (CARDIOVASC), Physiopharmacology (PHYSPHAR)
Anthracyclines (such as doxorubicin, DOX) are among the most effective chemotherapeutics and are widely used in modern cancer treatment despite the advent of targeted therapies. However, dose-dependent cardiotoxicity limits the clinical use of DOX. It is well documented that DOX may provoke cardiotoxicity leading to left ventricular dysfunction and eventually congestive heart failure. Recent studies have reported that anthracyclines also ...

Assessment of Patient Susceptibility to Cardiotoxicity by Chemotherapy KU Leuven

Lucas Van Aelst
Cardiology

The emergence of an ever-growing number of cancer therapies had a significant impact on cancer survival rates and converted a terminal illness into a chronic disease. Unfortunately, cancer treatment success has been offset by increased morbidity and mortality due to treatment related comorbidities. Cardiovascular complications are among the most frequent side effects and it is often said that ‘the oncology patient of today is the cardiology ...

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition (INSPIRE). University of Antwerp

Pieter-Jan Guns
Cardiovascular diseases (CARDIOVASC), Physiopharmacology (PHYSPHAR)
New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pharmacology (SP) aims to detect, understand and reduce undesirable pharmacodynamic effects early-on. Especially, cardiovascular (CV) toxicity is problematic, as it is the most prevalent reason for failure during preclinical development. Moreover, CV toxicity remains a key reason for drug attrition during ...